Akoya Biosciences, Inc. announced on April 23, 2025, a collaboration with the Singapore Translational Cancer Consortium (STCC) on the STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study. This initiative aims to identify and validate key biomarkers predicting response or refractoriness to immune checkpoint inhibitors.
The SUPER study is the first of its kind in Singapore, focusing on a unique case-control pan-cancer cohort of 200 patients, comprising 100 exceptional responders matched with 100 hyperprogressors to immune checkpoint inhibitors. Akoya’s IO60 panel will be utilized for spatial proteomic analysis within this study.
This collaboration expands Akoya's international research footprint and validates the utility of its IO60 panel for precision immunotherapy. The study's findings could have significant implications for future cancer immunotherapy approaches and healthcare cost optimization, enhancing Akoya's reputation in clinical research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.